Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Britain's FTSE rises as Shire surges

Fri, 16th Oct 2015 15:12

* Shire lifted by talk it may bid for a U.S. rival

* Burberry extends previous day's slide

* GKN hit by estimates downgrade from Liberum

By Kit Rees

LONDON, Oct 16 (Reuters) - Britain's top share index rose onFriday, lifted by drugmaker Shire, whose shares rose onspeculation it could be lining up a bid for a U.S. rival.

The blue-chip FTSE 100 index was up by 0.4 percentat 6,361.05 points going into the close of the trading session.

Shire rose 3.2 percent, which traders attributed to marketspeculation it was preparing a bid for U.S. peer Radius Health,seen as a potentially good deal for the British group.

Officials at Shire could not be immediately reached forcomment.

Traders added that expectations of new stimulus measuresfrom China, the world's second-biggest economy, were givingequity markets a further lift.

"With half an eye on the possibility of more central bankstimulus, stocks have edged out a positive finish to the week,"said CMC Markets analyst Jasper Lawler.

Burberry was among the worst performing stocks onthe FTSE, falling 2.1 percent to extend the previous session'sslide, as a profit warning late on Thursday from Hugo Boss hit luxury goods companies.

Hugo Boss cut its 2015 sales and profit outlook, while pricetarget cuts from brokers on Burberry's shares on Friday addedfurther pressure to the British company, whose shares hadalready slumped 8.3 percent on Thursday on weak sales growth.

GKN and other engineering stocks fell afterbrokerage Liberum cut its estimates across the sector. (Editing by Toby Chopra and Mark Potter)

Related Shares

More News
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...

29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while a...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.